Transferrin Receptor‐1: Expression in Canine Mammary Tumours and In Vitro Therapeutic Applications
Veterinary and Comparative Oncology · 2025
DOI: 10.1111/vco.70000 ↗Kurz gefasst
Fachartikel in der Zeitschrift Veterinary and Comparative Oncology, 2025. Verfasst von Valentina Moccia und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Comparative Biomedicine, Health and Food Science, University of Padua, Legnaro, Italy. Hauptthemen laut MEDLINE: Receptors, Transferrin, Dog Diseases, Mammary Neoplasms, Animal, Doxorubicin. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The transferrin receptor‐1 (TFR‐1) is overexpressed in many types of human cancers and, in recent years, several studies have investigated its use as a preferential channel for drug cellular uptake in cancer therapy. In veterinary medicine, TFR‐1 expression in cancer cells and tissues has been poorly described, as well as its therapeutic potential. In this study we investigated TFR‐1 expression in different subtypes of canine mammary tumours (CMTs) and in two CMT cell lines, one primary (CIPp) and one metastatic (CIPm). Additionally, we also compared the in vitro efficacy of an engineered human apoferritin nanocage loaded with doxorubicin (HFn(DOX)) with the conventional doxorubicin treatment on CIPp and CIPm. In CMT tissues, TFR‐1 was more expressed in the tumoral tissues compared to the hyperplastic counterparts, specifically with regards to carcinoma and malignant myoepithelioma and simple carcinoma subtypes ( p < 0.05). CIPp and CIPm did not show any significant difference in TFR‐1 protein expression, while TFR‐1 gene expression was higher in CIPm ( p < 0.05). The treatment with HFn(DOX) was more efficient than free doxorubicin only on CIPp at high concentrations (50 μM). In conclusion, we show for the first time the variability of TFR‐1 expression in CMT tissues and cell lines. Although further investigations are necessary, HFn can be loaded with different chemotherapeutic compounds, becoming an innovative therapeutic tool for the treatment of cancers highly expressing TFR‐1 in veterinary and human medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Comparative Biomedicine, Health and Food Science, University of Padua, Legnaro, Italy.
- Department of Animal Medicine, Production and Health, University of Padua, Legnaro, Italy.
- Department of Biotechnologies and Biosciences, University of Milan Bicocca, Milano, Italy.
ORCID-Profile: Valentina Moccia, Alessandro Sammarco
Zitieren
APA
Moccia, V., Rensi, N., Marullo, G. P., Sammarco, A., Bonsembiante, F., Torrigiani, F., Salvioni, L., Prosperi, D., Zappulli, V., & Cavicchioli, L. (2025). Transferrin Receptor‐1: Expression in Canine Mammary Tumours and In Vitro Therapeutic Applications. Veterinary and Comparative Oncology. https://doi.org/10.1111/vco.70000
Vancouver
Moccia V, Rensi N, Marullo GP, Sammarco A, Bonsembiante F, Torrigiani F, et al. Transferrin Receptor‐1: Expression in Canine Mammary Tumours and In Vitro Therapeutic Applications. Veterinary and Comparative Oncology. 2025. doi:10.1111/vco.70000
BibTeX
@article{Moccia2025,
author = {Moccia, Valentina and Rensi, Nicolò and Marullo, Giovanni Paolo and Sammarco, Alessandro and Bonsembiante, Federico and Torrigiani, Filippo and Salvioni, Lucia and Prosperi, Davide and Zappulli, Valentina and Cavicchioli, Laura},
title = {Transferrin Receptor‐1: Expression in Canine Mammary Tumours and In Vitro Therapeutic Applications},
journal = {Veterinary and Comparative Oncology},
year = {2025},
doi = {10.1111/vco.70000}
}
EUVIMED